Details of Drug-Metabolizing Enzyme (DME)
| General Information of DME (ID: DMEN060) | |||||
|---|---|---|---|---|---|
| DME Name | Cytochrome P450 (CYP), . | ||||
| Gene Name | CYP | ||||
| Click to Show/Hide the Molecular/Functional Data (Sequence/Structure/Pathway/Function) of This DME | |||||
| Full List of Drug(s) Metabolized by This DME | |||||
|---|---|---|---|---|---|
| Drugs Approved by FDA | Click to Show/Hide the Full List of Drugs: 11 Drugs | ||||
Nipradilol |
Drug Info | Approved | Angina pectoris | ICD11: BA40 | [1] |
Betrixaban |
Drug Info | Approved | Venous thromboembolism | ICD11: BD72 | [2] |
Emedastine |
Drug Info | Approved | Conjunctivitis | ICD11: 9A60 | [3] |
Mephentermine |
Drug Info | Approved | Essential hypertension | ICD11: BA00 | [4] |
Methadone |
Drug Info | Approved | Anaesthesia | ICD11: 8E22 | [5] |
Altretamine |
Drug Info | Approved | Ovarian cancer | ICD11: 2C73 | [6] |
Brompheniramine |
Drug Info | Approved | Allergic rhinitis | ICD11: CA08 | [7] |
Cetrorelix |
Drug Info | Approved | Ovarian stimulation | ICD11: LB45 | [8] |
Osilodrostat |
Drug Info | Approved | Cushing syndrome | ICD11: 5A70 | [9] |
Bromodiphenhydramine |
Drug Info | Approved | Allergic rhinitis | ICD11: CA08 | [10] |
Dexbrompheniramine |
Drug Info | Approved | Allergic rhinitis | ICD11: CA08 | [11] |
| Drugs in Phase 3 Clinical Trial | Click to Show/Hide the Full List of Drugs: 1 Drugs | ||||
TAK-700 |
Drug Info | Phase 3 | Prostate cancer | ICD11: 2C82 | [12] |
| Drugs in Phase 2 Clinical Trial | Click to Show/Hide the Full List of Drugs: 2 Drugs | ||||
Remogliflozin etabonate |
Drug Info | Phase 2 | Type-1/2 diabetes | ICD11: 5A10-5A11 | [13] |
SMT-C1100 |
Drug Info | Phase 2 | Muscular dystrophy | ICD11: 8C70 | [14] |
| Discontinued/withdrawn Drugs | Click to Show/Hide the Full List of Drugs: 3 Drugs | ||||
ABT-418 |
Drug Info | Discontinued in Phase 2 | Alzheimer disease | ICD11: 8A20 | [15] |
ABT-418 |
Drug Info | Discontinued in Phase 2 | Alzheimer disease | ICD11: 8A20 | [16] |
FLM-5011 |
Drug Info | Discontinued in Phase 1 | Inflammation | ICD11: 1A00-CA43 | [17] |
| References | |||||
|---|---|---|---|---|---|
| 1 | Metabolism of nipradilol by liver homogenates from different species. I. Comparative studies on the denitration of nipradilol and other organic nitrates | ||||
| 2 | Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism | ||||
| 3 | Emedastine-ketoconazole: pharmacokinetic and pharmacodynamic interactions in healthy volunteers | ||||
| 4 | Metabolism of mephentermine and its derivatives by the microsomal fraction from male Wistar rat livers | ||||
| 5 | Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics | ||||
| 6 | Hexamethylmelamine: pharmacology and mechanism of action | ||||
| 7 | U. S. FDA Label -Brompheniramine | ||||
| 8 | Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds | ||||
| 9 | DrugBank(Pharmacology-Metabolism):Osilodrostat | ||||
| 10 | U. S. FDA Label -Bromodiphenhydramine | ||||
| 11 | U. S. FDA Label -Dexbrompheniramine | ||||
| 12 | Preclinical assessment of Orteronel(?), a CYP17A1 enzyme inhibitor in rats | ||||
| 13 | Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies | ||||
| 14 | Isolation, Structural Identification, Synthesis, and Pharmacological Profiling of 1,2-trans-Dihydro-1,2-diol Metabolites of the Utrophin Modulator Ezutromid | ||||
| 15 | In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N'-oxidation | ||||
| 16 | The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans | ||||
| 17 | U. S. FDA Label -FLM-5011 | ||||
| 18 | Alfentanil pharmacokinetics and metabolism in humans Anesthesiology. 1988 Oct;69(4):527-34. doi: 10.1097/00000542-198810000-00012. | ||||
| 19 | Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling | ||||
| 20 | In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos. 2010 Oct;38(10):1688-97. | ||||
| 21 | Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug-metabolizing enzymes. Chirality. 2005 Mar;17(3):135-41. | ||||
| 22 | Genistein: Dual Role in Women's Health | ||||
| 23 | Adrenic Acid-Derived Epoxy Fatty Acids Are Naturally Occurring Lipids and Their Methyl Ester Prodrug Reduces Endoplasmic Reticulum Stress and Inflammatory Pain | ||||
| 24 | Metabolism of adrenic acid to vasodilatory 1alpha,1beta-dihomo-epoxyeicosatrienoic acids by bovine coronary arteries | ||||
| 25 | Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact. 2001 Jan 30;130-132(1-3):737-48. | ||||
| 26 | Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005 Dec;35(12):1121-33. | ||||
| 27 | Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. | ||||
| 28 | Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state Drug Metab Dispos. 2010 May;38(5):808-16. doi: 10.1124/dmd.109.030833. | ||||
| 29 | Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats Drug Metab Dispos. 2008 Dec;36(12):2523-38. doi: 10.1124/dmd.108.022962. | ||||
| 30 | Crude Edible Fig (Ficus carica) Leaf Extract Prevents Diethylstilbestrol (DES)-Induced DNA Strand Breaks in Single-Cell Gel Electrophoresis (SCGE)/Comet Assay: Literature Review and Pilot Study J Bioequivalence Bioavailab. 2019;11(2):19-28. doi: 10.35248/0975-0851.19.11.389. | ||||
| 31 | Identification of a hydroxy metabolite of diflunisal in rat and human urine Xenobiotica. 1991 Nov;21(11):1521-33. doi: 10.3109/00498259109044402. | ||||
| 32 | Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Mol Pharmacol. 1991 Nov;40(5):859-67. | ||||
| 33 | Hydroxysteroid sulfotransferase and a specific UDP-glucuronosyltransferase are involved in the metabolism of digitoxin in man. Naunyn Schmiedebergs Arch Pharmacol. 1992 Aug;346(2):226-33. | ||||
| 34 | LABEL:IHYDROERGOTAMINE MESYLATE- dihydroergotamine spray | ||||
| 35 | Determination of linopirdine and its N-oxide metabolites in rat plasma by liquid chromatography | ||||
| 36 | Comparative In vitro Metabolism of Enflicoxib in Dogs, Rats, and Humans: Main Metabolites and Proposed Metabolic Pathways | ||||
| 37 | Comparative pharmacokinetics of the histamine H1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys | ||||
| 38 | Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7. | ||||
| 39 | Biodegradation of Ephedrine Isomers by Arthrobacter sp. Strain TS-15: Discovery of Novel Ephedrine and Pseudoephedrine Dehydrogenases | ||||
| 40 | Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther. 2013 Feb;344(2):388-96. | ||||
| 41 | Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor | ||||
| 42 | Metabolic fate of fenetylline in rat and man | ||||
| 43 | The participation of human hepatic P450 isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion. Toxicol Appl Pharmacol. 2008 Dec 1;233(2):343-52. | ||||
| 44 | Pharmacokinetic properties and metabolism of idebenone J Neurol. 2009 Mar;256 Suppl 1:31-5. doi: 10.1007/s00415-009-1006-z. | ||||
| 45 | Biotransformation of [(14)C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces Cancer Chemother Pharmacol. 2018 Nov;82(5):803-814. doi: 10.1007/s00280-018-3671-z. | ||||
| 46 | In situ metabolism of levetiracetam in blood of patients with epilepsy | ||||
| 47 | Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers | ||||
| 48 | Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase I poisons | ||||
| 49 | New Anti-Inflammatory Metabolites by Microbial Transformation of Medrysone PLoS One. 2016 Apr 22;11(4):e0153951. doi: 10.1371/journal.pone.0153951. | ||||
| 50 | Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991. | ||||
| 51 | The Metabolism of Methazolamide in Immortalized Human Keratinocytes, HaCaT Cells | ||||
| 52 | Evidence for the involvement of N-methylthiourea, a ring cleavage metabolite, in the hepatotoxicity of methimazole in glutathione-depleted mice: structure-toxicity and metabolic studies | ||||
| 53 | Kinetics of in vitro metabolism of methoxyphenamine in rats | ||||
| 54 | Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study | ||||
| 55 | Pharmacological profile and effects of mitotane in adrenocortical carcinoma | ||||
| 56 | Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001 Dec;29(12):1548-54. | ||||
| 57 | Oxidative denitrification of 2-nitropropane and propane-2-nitronate by mouse liver microsomes: lack of correlation with hepatocytotoxic potential | ||||
| 58 | Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats Biochem Pharmacol. 1983 May 1;32(9):1487-93. doi: 10.1016/0006-2952(83)90470-7. | ||||
| 59 | Self-induction by oleandomycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Comparison with troleandomycin J Pharmacol Exp Ther. 1982 Apr;221(1):215-21. | ||||
| 60 | Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes | ||||
| 61 | Protection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against light-induced damage in rats | ||||
| 62 | First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile | ||||
| 63 | Improved oral bioavailability in rats of SR13668, a novel anti-cancer agent | ||||
| 64 | A Phase 1, Randomized, Single-Dose Crossover Pharmacokinetic Study to Investigate the Effect of Food Intake on Absorption of Orteronel (TAK-700) in Healthy Male Subjects | ||||
| 65 | Evaluation of the Mass Balance and Metabolic Profile of Futibatinib in Healthy Participants | ||||
| 66 | Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet. 2005;44(9):915-34. | ||||
| 67 | Stable isotope- and mass spectrometry-based metabolomics as tools in drug metabolism: a study expanding tempol pharmacology | ||||
| 68 | Metabolism of a dithiocarbamate fungicide thiram to carbon disulfide in the rat and its hepatotoxic implications | ||||
| 69 | Vericiguat: A New Hope for Heart Failure Patients | ||||
| 70 | Metabolic fate of a new histamine H2-receptor antagonist, Z-300, in rat | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.